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Abstract 
Introduction: Self-efficacy (SE) refers to one’s belief in their ability to successfully complete a 
task. Increases in SE are associated with improved pain outcomes as well as improvements in 
anxiety and depression (Turner, 2005). Headache-related self-efficacy (HSE) refers to a person’s 
belief in his/her ability to manage migraine attacks. Previous studies illustrate that HSE and 
psychiatric comorbidities are independently related to migraine disability, severity, and treatment 
outcomes. The purpose of the present study was to assess the relationship between HSE and 
psychiatric comorbidities among individuals with migraine.  
 
Methods: 852 young adult migraineurs (M age = 19.22; 79.9% female; 77.0% Caucasian) 
completed measures about headache and related variables, including the Headache Management 
Self-Efficacy Scale (HMSE; French, 2000), the Depression Anxiety Stress Scale (DASS-21; 
Lovibond, 1995), and the Post-traumatic Stress Disorder Checklist (PCL; Wilkins, 2011). Of the 
852 migraine participants, 56.8% met criteria for migraine without aura, 25% met for migraine 
with aura, and 18.2% met for chronic migraine. Linear regressions were run to identify 
associations between psychiatric symptoms (depression, anxiety, and PTSD) and HSE. 
 
Results: Men reported higher HSE than women (M = 108.67 [18.91] vs. 104.66 [21.28], p = 
.025). Comorbid psychiatric symptoms explained a significant proportion of variance in HSE 
scores (R2 = .047, p < .001). When controlling for sex, headache frequency, and disability, the 
percentage of unique variance accounted for by psychiatric comorbidities was 1.5% (p = .005) of 
the total. 
 
Conclusion: Consistent with our hypothesis, a significant relationship exists between comorbid 
psychiatric symptoms and HSE scores, but psychiatric symptoms only accounted for a small 
amount of variance in HSE. This small effect size likely indicates that numerous variables 
influence self-efficacy, and that psychiatric symptoms represent a relatively weak influence; 
perhaps also stronger relations would be evident in a clinical sample. Future research into 
variables that affect headache-related self-efficacy would be valuable for piecing together a 
better understanding of this powerful predictor of headache prognosis.  
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Psychiatric Symptomatology in Migraine Sufferers and the Relationship with Headache-
Related Self-Efficacy 
By: Lindsay W. Wencel 
 
Migraine 
Diagnosis 
Migraine sufferers experience headache attacks lasting between 4 and 72 hours if 
untreated (International Headache Society [IHS], 2013). The pain is characterized by two or 
more of the following; unilateral location, pulsating/throbbing pain, moderate to severe intensity, 
or aggravation by normal activity. These attacks must also be accompanied by nausea or 
vomiting or both photophobia (sensitivity to light) and phonophobia (sensitivity to sound). The 
headache must also not be attributable to any other condition such as substance use, head/neck 
trauma, or another disorder.  Migraine is divided into two subtypes, episodic and chronic, based 
upon frequency of headache attacks. Episodic migraine occurs on less than 15 days per month, 
while chronic migraine exhibits the above characteristics but has a frequency of at least 15 
headache days per month, with migraine symptoms on at least eight of those days. For the 
condition to be considered chronic, this frequency must be maintained for a period of time 
greater than three months. 
 Migraine with aura is less common than migraine without aura, affecting 25% of all 
migraine sufferers. Aura presents as temporary symptoms that are precursors of the actual 
headache attack, and the patient must have experienced at least two headaches with aura (IHS, 
2013). The aura symptoms are usually visual in nature (e.g., blurred vision, zigzag lines), though 
sensory, speech/language, motor, brain stem or retinal disturbances occur in a minority of those 
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with aura. Aura symptoms typically develop gradually over 5-20 minutes, last less than an hour, 
and then resolve coinciding with onset of head pain.  
 
Prevalence and Burden 
 Migraine is very common, with data from the World Health Organization indicating that 
migraine is the third most prevalent medical condition worldwide (Vos, Flaxman, Naghavi, 
Lozano, Michaud, and Ezzati, 2012). In the US, migraine has a lifetime prevalence of 43% for 
women and 18% for men (Stewart, Wood, Reed, Roy, & Lipton, 2008). Episodic migraine is the 
most common form of migraine and was found in a 2012 survey study of more than 160,000 
American adults to have a yearly prevalence of 12% (Buse et al., 2012).  Chronic migraine is far 
less common than episodic, affecting approximately 1% of the general population.  
Both nationally and globally, migraine is a significant source of disruption in sufferers’ 
lives, leading to a decrease in overall work, school, home, and personal functioning (Vos et al., 
2012). Financially, migraine costs the US between $13 and $17.2 billion each year when 
considering direct and indirect expenses related to the disorder (Pesa & Lage, 2004). Headache is 
the fifth most common cause of emergency room visits nationally and accounts for a large 
proportion of medical expenses each year (Pesa & Lage, 2004; Smitherman, Burch, Sheikh, & 
Loder, 2013). Individually, migraineurs spend more than twice their non-migraine counterparts 
on medical care each year (Pesa & Lage, 2004). They also have more sick days and an overall 
decrease in job performance compared to those without migraine (Pesa & Lage, 2004; Singh, 
2014). 
 Migraine causes reductions in school or work performance, household responsibilities, 
and social and leisure activity participation (Leonardi, 2010). A World Health Organization 
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study found migraine to be the 8th most disabling condition worldwide (Vos et al., 2012), and 66-
93% of migraine sufferers experience moderate to severe disability (Bera, Khandelwal, Sood, & 
Goyal, 2014; Lipton et al., 2007). Migraine is also associated with decreased quality of life 
(Leonardi, Raggi, Bussone, & D'Amico, 2010; Paschoal et al., 2013), and this burden increases 
with migraine frequency. People with chronic migraine experience higher disability than those 
with episodic migraine (Buse et al., 2012). Other factors associated with increased migraine 
disability associated include female gender, high stress, symptom severity, and presence of 
psychiatric comorbidity (Buse, Silberstein, Manack, Papapetropoulos, & Lipton, 2013). 
 
Pathophysiology 
 Several hypotheses for the causes of migraine have been presented, but currently there is 
not a consensus for its pathophysiology. One of the earliest hypotheses for the cause of migraine 
was cerebral vasoconstriction followed by vasodilation (Horváth, 2014). This vascular theory 
seemed to be supported by the efficacy of triptans for migraine, which effect vascular changes in 
the brain. Further research has discredited the vascular theory by showing that vascular changes 
are not a primary cause of headache but instead secondary to other initiating events. The current 
accepted theory of migraine is the neurovascular theory, which asserts that migraine is 
attributable to a hypersensitive central nervous system and influenced both by brain stem and 
cortical structures.  
 Genetics also play a role in migraine, which has a heritability of 30–60%, with a higher 
probability for inheritance for migraine with aura (Chasman et al., 2014). Chasman et al. (2014) 
identified 12 single nucleotide polymorphisms (SNPs) that show evidence of association with 
migraine in women. Their research also discovered SNPs associated with migraine 
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nonspecifically, migraine with aura, specific migraine characteristics, and development of other 
body systems involved in migraine, such as neurotransmitter systems and vascular development. 
This information has the potential to open new avenues for migraine diagnosis and treatment, but 
a comprehensive account of migraine pathophysiology remains elusive. 
 
Treatment 
 Management of attacks is crucial to the well-being of individuals who experience 
migraine and is divided into preventive and acute treatment. Preventive treatment is used to 
decrease the frequency of attacks. When patients experience frequent migraine attacks (at least 4-
6 attacks per month) or require acute treatment more than twice in a week period, then a 
preventive medication is indicated (Singh, 2014). The most effective of these medications are 
beta-blockers, tricyclic antidepressants, and anti-convulsants, taken on a daily basis. Along with 
pharmacologic interventions, behavioral modifications such as improving sleeping habits, 
exercising, stopping smoking, managing weight, and avoiding triggers are also recommended 
(Lipton et al., 2007; Singh, 2014).  Psychological treatments, such as relaxation training, various 
forms of biofeedback, and cognitive behavioral therapy, have also shown efficacy for migraine 
similar to that observed with the best preventive medications (Wells & Loder, 2012). 
 Acute treatments are used in the event of a migraine attack and usually shorten the 
duration of the attack and improve symptoms. Triptans are the most commonly used agents and 
are effective in treating attacks if used early enough in the episode (Singh, 2014). They have 
cardiovascular contraindications and side effects, which prohibit some sufferers from utilizing 
them. In cases of severe migraine, anti-emetics and ergot derivatives are also used. 
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 When comorbid disorders are present, treating the comorbid disorder can also lead to a 
reduction in migraine attacks as well as severity of attacks. A study by Calhoun et al. (2007) 
found that treating sleep disturbance in individuals with chronic migraine and insomnia led to a 
reduction in headache frequency. Similar results have also been illustrated in cases of comorbid 
obesity (Bond, Roth, Nash, & Wing, 2011). 
  
Psychological Factors in Migraine 
 Several studies have shown that psychiatric symptoms commonly occur in migraine 
sufferers, with 25- 62.5% of all sufferers having a lifetime diagnosis of at least one psychiatric 
comorbidity (Bera et al., 2014; Buse et al., 2013; Semiz, Sentürk, Balaban, Yagiz, & Kavakçi, 
2013). Psychiatric disorders are two to ten times as prevalent in those with migraine as in the 
general population (Buse et al., 2013). Comorbidities are significantly more common in female 
migraineurs than their male counterparts, likely due to hormonal and serotonin influences on 
both conditions (Baskin & Smitherman, 2009). Studies have demonstrated that psychiatric 
comorbidities have an adverse impact on headache-related disability, headache severity, quality 
of life, and both treatment adherence and outcomes (Baskin & Smitherman, 2009; Semiz et al., 
2013). Comorbid psychiatric symptoms also increase the likelihood of headache chronification, 
or the transition from episodic to chronic frequency of migraine (Buse et al., 2013). Treatment of 
migraine with psychiatric comorbidities is further complicated due to the fact that several 
common medications for migraine exacerbate psychiatric conditions (Finocchi, Villani, & 
Casucci, 2010).  
 Increased rates of psychiatric comorbidities occur not only among older treatment-
seeking patients but also among young adult or college student migraineurs.  In a study by Semiz 
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et al. (2013), of 169 college students who experience migraine, at least one diagnosable 
psychiatric disorder was found in 23.1% of the participants. Further, 43.2% of migraineurs 
surveyed had a psychiatric diagnosis at some point in their lives. Those individuals with 
comorbidities were also found to have more frequent, severe and disabling headaches. 
 
Anxiety 
Several studies have illustrated that, of all the affective disorders, anxiety has the 
strongest association with migraine (Baskin & Smitherman, 2009; Hamelsky & Lipton, 2006). 
Comorbid anxiety is associated with increased headache intensity and disability as well as 
significantly reduced quality of life (Baskin & Smitherman, 2009; Oh, Soo-Jin Cho, Yun, Jae-
Moon Kim, & Min, 2014; Paschoal et al., 2013). Anxiety is a strong contributing factor to 
migraine persistence, chronification and worsened overall prognosis (Baskin et al., 2009; Buse et 
al., 2013). Comorbid anxiety is also associated with doubled total medical costs compared to 
having migraine without anxiety (Pesa & Lage, 2004).  
The prevalence of generalized anxiety disorder (GAD) and subclinical anxiety symptoms 
among those with migraine differs by population, with between 5-34% of sufferers presenting 
diagnosable GAD (Bera et al., 2014; Bhatia & Gupta, 2012; Semiz et al., 2013. In general, 
migraine sufferers are between 4 and 5 times as likely to have GAD as those without migraine 
(Semiz et al., 2013). Similarly, panic disorder, another anxiety disorder, is 3.76 times as likely in 
migraineurs than in the general population (Smitherman, Kolivas, & Bailey, 2013). This 
increased in prevalence of anxiety disorders could be due to an increase in stress from migraine 
attacks, anxiety operating as a migraine trigger, or maladaptive coping behaviors that develop in 
response to headaches (Radat et al., 2008). The relationship between migraine and anxiety has 
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been shown to be bidirectional, in that people with anxiety are also more likely to develop 
migraine (Baskin & Smitherman, 2009; Hamelsky et al., 2006).  
 
Depression 
 Between 14-37.5% of migraineurs experience depression or depressive symptoms 
(Baskin et al., 2009; Bera et al., 2014; Bhatia et al., 2012; Semiz et al., 2013). Several studies 
have shown that people with migraine are between 2-4 times as likely to develop depression 
when compared with the general population (Baskin & Smitherman, 2009, Buse et al., 2013; 
Hamelsky et al., 2006), and rates are highest among migraineurs with aura and those with 
chronic migraine. 
 As with anxiety, there is a bidirectional relationship between migraine and depression, 
but it is slightly more common to develop depression after migraine than vice versa (Hamelsky 
et al., 2006). The high frequency of depression with migraine may be due to the unpredictability 
of migraine attacks and the perceived inability to control attacks, as well as the effects of reduced 
serotonergic transmission seen in both conditions. (Baskin & Smitherman, 2009; Hamelsky et 
al., 2006). As with anxiety, depression is linked with higher medical costs. (Pesa & Lage, 2004). 
 Comorbid depression is related to an increase in frequency, symptomatology and severity 
of migraine, as well as, an increased risk for chronification (Buse et al., 2013; Ching-I Hung, 
Chia-Yih Liu, Yeong-Yuh Juang, & Shuu-Jiun Wang, 2006; Finocchi et al. , 2010; Hamelsky et 
al., 2006). Migraineurs with depression also have a marked decrease in functioning and overall 
quality of life and an increase in headache-related disability (Hamelsky et al., 2006) (Paschoal et 
al., 2013). Furthermore, migraine sufferers have more severe depression and higher risk of 
suicide attempts than those with depression but without migraine (Baskin & Smitherman, 2009) 
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(Buse et al., 2013). Treatment of migraine has been shown to have positive effects on depressive 
symptoms (Buse et al., 2013), but most studies of antidepressant migraine agents have excluded 
depressed patients.  
 
Combined Anxiety and Depression 
 Both anxiety and depression occur jointly with migraine, specifically in those individuals 
with chronic migraine (Hamelsky et al., 2006; Radat et al., 2008). Mixed anxiety and depression 
has been found to have a prevalence of 18% in migraineurs (Bhatia et al., 2012). A population 
study of almost 3000 participants found that two-thirds of all migraine sufferers with depression, 
also had anxiety, and that one-third of sufferers with anxiety also had depression (Oh et al., 
2014). Individuals presenting with both anxiety and depression are at twice the risk of 
developing migraine than their non-anxious, non-depressed counterparts (Hamelsky et al., 2006). 
 The combination of anxiety and depression has been related to increased headache 
frequency and higher risk of migraine chronification (Oh et al., 2014). Individuals with both 
anxiety and depression also take significantly more acute medications and experience decreased 
effectiveness of those medications (Radat et al., 2008). This leads to an even more significant 
increase in stress and decrease in quality of life than either comorbid anxiety or depression alone 
(Paschoal et al., 2013; Radat et al., 2008). In the case of this dual-comorbidity, treatment of one 
of these disorders has the potential to improve all three conditions (Hamelsky et al., 2006). 
 
Post-traumatic Stress Disorder 
 Post-traumatic stress disorder is a psychiatric disorder characterized by exposure to a 
traumatic event or events, including death, threatened death, actual or threatened serious injury, 
Wencel 13 
or actual or threatened sexual violence (American Psychiatric Association [APA], 2013). This 
exposure must be followed by persistently re-experiencing the event via intrusive recollections, 
dissociative reactions, nightmares, increased physiologic reactivity, or distress at exposure to 
traumatic reminders and the development of avoidance behavior. Individuals with PTSD also 
must experience negative changes in thought process and mood as well as arousal and reactivity 
as a result of the trauma they experienced. These symptoms must persist of a period of time 
greater than a month and cannot be related to any other physical or psychological disorder.  In 
the general population, PTSD has a lifetime prevalence of 8.3% (Kilpatrick et al., 2013). PTSD 
is significantly more prevalent in migraine patients than in the general population (Peterlin et al., 
2009). Numerous studies have demonstrated a strong association between PTSD and migraine, 
with prevalence rates between 22-50% of migraine sufferers (Buse et al., 2013; Semiz et al., 
2013).  
 Traumatic events are more common among those with migraine than in the general 
population. A study by Peterlin et al. (2007), examining headache patients presenting at tertiary 
care clinics, found that 27.3% of migraine patients had experienced some form of physical or 
sexual abuse. Peterlin et al. (2008) studied a group of 62 migraine patients and found diagnostic 
criteria for PTSD were met in 12.5% of episodic migraineurs and in 42.9% chronic migraineurs 
(Peterlin, Tietjen, Meng, Lidicker, & Bigal, 2008). Another study of 80 migraine and tension-
type headache patients found similar results, with 25% of patients exhibiting evidence of current 
PTSD (De Leeuw, Schmidt, & Carlson, 2005). These studies, as well as others, indicate that 
PTSD is significantly more common in those with chronic migraine (Buse et al., 2013; Peterlin 
et al., 2008). Unlike other psychiatric comorbidities, the dual diagnosis of migraine and PTSD is 
significantly more prevalent in men (Peterlin, Calhoun, & Balzac, 2012). Further study by 
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Smitherman et al. (2013) determined that PTSD, not merely exposure to trauma, is most 
associated with migraine diagnosis. 
 Comorbid PTSD is associated with higher risk for chronification of migraine and 
intensified headache severity (Peterlin et al., 2009; Peterlin et al., 2008; Smitherman & Kolivas, 
2013). Post-traumatic symptoms are positive correlated with headache-related disability, so as 
PTSD worsens so does migraine disability (Smitherman & Kolivas, 2013). PTSD has also been 
linked to poorer coping mechanisms and prognosis as well as a heightened risk of developing 
medication overuse headache. Post-traumatic symptoms have also been associated with new or 
worsening depression in migraine patients (Peterlin et al., 2009). Considered in conjunction, 
psychological disorders and symptoms are critical in understanding and treating migraine. Most 
recently, interest in psychological factors has expanded beyond disorders and into other 
psychological constructs, such as self-efficacy.  
 
Self-efficacy 
 Self-efficacy is a person’s belief in her ability to complete a given task or achieve a 
desired outcome (Bandura, 2014; Yancey, 2014). It is the basis for one’s interactions with their 
environment, effecting initiation, persistence, and success in all ventures. Self-efficacy is 
developed based upon past experiences of success or failure, witnessed success or failure of 
others, and other’s opinions about a person's abilities. Individuals with high self-efficacy believe 
that they are in control of their circumstances, which leads to enhanced task performance and, in 
turn, additional increases in self-efficacy. Conversely, those with low self-efficacy believe that 
success is out of their hands and expect failure when attempting new tasks. This defeatist 
mindset often leads to failure and worsening of self-efficacy, or an unwillingness to even attempt 
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a certain action. Stress and anxiety can lead to marked decrease in task performance and self-
efficacy, which can precipitate or worsen anxiety and depression and lead to a continuous cycle 
of anxiety, failure, and low self-efficacy. 
 Improving self-efficacy has been shown to have positive effects on medical outcomes. In 
a review article by Magklara et al. (2014), post-operative self-efficacy in joint replacement 
patients was a significant determinant of both short and long term recovery outcomes. A study by 
Turner et al (2005), consisting of 140 elderly adults with chronic pain, found that increased self-
efficacy was modestly, but significantly, associated with decreases in disability and depressive 
symptoms. Furthermore, a study by Hadjistavropoulos et al. (2007) of recurrent pain in a college 
population found that heightened self-efficacy was highly correlated with improved coping 
methods and functioning. High self-efficacy was also negatively correlated with pain intensity 
and impairment, as well as negative affect. Self-efficacy, and the positive outcomes related to it, 
has similar value in migraine sufferers as in other pain patients.  
 
Headache-Related Self-Efficacy 
 Headache-related self-efficacy is defined as one’s confidence in her ability to properly 
manage and prevent headaches (Seng & Holroyd, 2010). Research into headache-related self-
efficacy is fairly new area of study, but early studies have provided noteworthy results. Headache 
severity and disability are inversely correlated with headache-related self-efficacy (Paschoal et 
al., 2013), and high self-efficacy is also correlated with a decrease in anxiety (French et al., 
2000). Conversely, low self-efficacy has been related to decreased pain tolerance (French et al., 
2000). 
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Significant evidence exists showing psychological treatments, such as behavioral 
migraine management strategies; improve headache-related self-efficacy in episodic migraineurs 
(Nicholson, 2005; Seng & Holroyd, 2010; Sorbi, Kleiboer, Van Silfhout, Vink, & Passchier, 
2014). A study of almost 200 migrainuers by Sorbi et al. (2014) found that online behavioral 
training in headache management significantly improved both headache and self-efficacy over a 
10-month period. Psychological treatments for improving headache-related self-efficacy have 
also shown efficacy for individuals with chronic migraine (Thorne et al., 2007). Further, 
Voerman et al. (2014) found that gains in headache outcomes and headache-related self-efficacy 
were maintained 2-4 years later. Improved headache-related self-efficacy has also been 
associated with utilization of positive coping strategies, along with better treatment adherence 
and improved prognosis (French et al, 2000; Seng & Holroyd, 2010). Although there has been 
significant research in to headache-related self-efficacy’s relationship to headache outcomes, few 
studies have explored variables that contribute to headache-related self-efficacy itself. 
  
Goal of this Study 
 Previous studies have demonstrated that both psychiatric comorbidities and headache-
related self-efficacy have significant relationships with migraine disability, severity, and 
treatment outcomes. Improvements in general self-efficacy are associated with improved 
outcomes and reductions in anxiety and depression in pain patients (Hadjistavropoulos et al, 
2007; Turner et al., 2005). Similar results have been found in migraine sufferers (French et al., 
2000; Peck, 2013; Seng & Holroyd, 2010), but studies are lacking exploring how headache-
related self-efficacy is associated with psychiatric comorbidities in migraineurs. This study’s 
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purpose is to examine the possible association between psychiatric comorbidities and headache 
self-efficacy among individuals with migraine.  
 
Hypothesis 
Study Goal 1: to investigate the association between headache self-efficacy and psychiatric 
comorbidities among individuals with migraine.  
Hypothesis 1a: Migraineurs with psychiatric comorbidity will have lower headache-
related self-efficacy than those without psychiatric comorbidity. 
Hypothesis 1b: Specific psychiatric comorbidities, such as anxiety, depression and PTSD, 
will have significant relationships with headache-related self-efficacy.  
 
Methods 
Participants 
  Participants were undergraduates recruited from introductory psychology courses at the 
University of Mississippi, using an online research management program, from 2011-2014. 
Those who chose to participate completed an online battery including questionnaires about 
psychiatric symptoms, specifically anxiety, depression, and PTSD, as well as a computerized 
headache diagnostic interview. Participants with primary episodic and chronic migraine (ICHD-
II codes 1.1, 1.2, 1.5.1, 1.6) diagnoses after exclusion of possible secondary causes and 
adherence to ICHD-II diagnostic criteria were retained for further study. Migraine criterion B, 
which dictates the duration of headache required to qualify as migraine, was decreased from 4 to 
2 hours due to previous studies indicating that young adults commonly experience migraine 
attacks with all other criteria but that are shorter than 4 hours (Rains, Penzien, Lipchik, & 
Wencel 18 
Ramadan, 2001; Rasmussen, Jensen, & Olesen 1991). Any participant with incomplete batteries 
in target areas was excluded. 
 
Materials 
 
The Depression Anxiety Stress Scales (DASS-21) The DASS was originally a 42-
question scale, with anxiety (DASS-A), depression (DASS-D), and stress (DASS-S) subscales 
created to quantify negative emotions over a week period (Antony, Bieling, Cox, Enns, & 
Swinson, 1998).  A shorter version, the DASS-21 was later released by Lovibond and Lovibond 
to decrease the time required for administration (Lovibond & Lovibond, 1995). The DASS-21 is 
a likert-type scale with high reliability and validity across populations (Oei, Sawang, Goh, & 
Mukhtar, 2013; Weiss, Aderka, Lee, Beard, & Björgvinsson, 2014). The DASS-21 has also 
shown validity across cultures (Mellor et al., 2014). The DASS-D is sensitive to alterations in 
depressive symptomatology (Weiss et al., 2014) and shows efficacy for screening PTSD in 
certain populations (Kok, De Haan, Van, Najavits, & De Jong, 2015). This measure is located in 
Appendix B. 
Headache Impact Test (HIT-6) The HIT-6 is a 6-item self-report survey for 
determining disability attributable to headache, in terms of changes in functioning and quality of 
life due to headache (Rains et al., 2001). The HIT-6 evaluates interference in cognitive, role, and 
social functioning as well as pain and psychological distress. This scale has strong validity and 
reliability in both episodic and chronic migraine sufferers (Rains, et al. 2001; Yang, Rendas-
Baum, Varon, & Kosinski, 2011). This measure is located in Appendix C. 
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Headache Management Self-Efficacy Scale (HMSE) The HMSE is a headache specific 
measure of self-efficacy, consisting of 25 questions, rated on a 1-7 likert-type scale (French et 
al., 2000). These questions quantify the confidence of those with headache in their own ability to 
prevent and manage headache attacks. The HMSE has been found to be both reliable and valid 
(Hansen, Bendtsen, & Jensen, 2009). This measure is located in Appendix D. 
The Post-traumatic Stress Disorder Checklist (PCL) The PCL is a 17 Likert-type item 
questionnaire that evaluates PTSD symptoms over the last month (Wilkins, Lang, & Norman, 
2011) resulting from experienced traumas. Three different forms of the PCL exist, one for 
military personnel (PCL-M), one for civilians (PCL-C), and one for specific traumatic events 
(PCL-S). This study utilized the PCL-C, which has been found to be highly reliable and have 
high validity (Conybeare, Behar, Solomon, Newman, & Borkovec, 2012; Wilkins et al., 2011).  
This measure is located in Appendix E. 
Structured Diagnostic Interview for Headache-Revised (SDIH-R) The SDIH is a 
computer-administered diagnostic interview for all major forms of (Andrew, Penzien, Rains, 
Knowlton, & McAnulty, 1992). The initial SDIH was a significant improvement in reliability 
and validity from previous diagnostic techniques. The measures utilized for the study was the 
SDIH-II, a more recent version revised to fit new International Headache Society parameters for 
headache diagnosis. This measures is located in Appendix A. 
 
 
Procedure 
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 Participants were undergraduate students enrolled in psychology courses at The 
University of Mississippi. They provided informed consent and completed the online measures 
as part of a larger battery and in exchange for modest course credit. 
 
Statistical Analyses 
 The study sample was summarized by descriptive statistics and distributions were 
examined. To understand how headache-related self-efficacy as well as other pertinent variables 
(anxiety, depression, headache disability, and PTSD) differed between migraine diagnoses, one-
way analysis of variance (ANOVA) tests were performed. Additionally, post-hoc tests of 
significant ANOVA results were conducted to determine which groups differed from each other. 
Finally, after collapsing all migraine subtypes, linear regressions were performed to examine the 
amount of variance in HSE scores attributable to the psychiatric symptoms.  
 
Results 
 
Participant Exclusions, Demographics, and Headache Diagnosis 
 Five thousand five hundred and eighty-three undergraduate students, ranging in age from 
18 to 46, initially participated in this study. Of those participants, 286 did not complete the 
appropriate measures to properly determine a headache diagnosis and were excluded. 
Additionally, all participants without headache and with other headache subtypes other than 
migraine and its variants were excluded [nonheadache (n = 1533), probable migraine (n = 1017), 
chronic TTH (n = 64), episodic TTH (n = 884), probable TTH (n = 791), cluster headache (n = 
82), MOH (n = 11)]. Of the remaining 1043 participants, 191 had incomplete self-efficacy data 
Wencel 21 
and were excluded. The remaining 852 with ICHD-II congruent migraine made up the final 
sample. 
 The sample had a mean age of 19.22 years (SD = 2.43) and was comprised of 79.9% 
females. The sample was predominantly Caucasian (77%) followed by African American 
(17.4%), Hispanic/Latino (2%), Multiracial (1.6%), Asian (1.4%), Native American/ Alaskan 
(0.5%), and Pacific Islander/Native Hawaiian (0.1%). Headache diagnosis for retained 
participants was primarily episodic migraine without aura (n= 484, 56.8%), followed by episodic 
migraine with aura (n= 213, 25%), and chronic migraine (n= 155, 18.2%). 
 
Covariates 
 To assess whether the main variables of interest differed as a function of gender, t-tests 
were conducted comparing males and females on the ASI total, DASS subscales, HIT-6, HMSE, 
and PCL (see Table 1). Of these, only headache self-efficacy differed as a function of gender, 
with men reporting higher self-efficacy than women (M = 108.67 [18.91] vs. 104.66 [21.28], p = 
.025). Gender was thus used as a covariate in later regression analyses. Headache frequency was 
also used as a covariate, given that those with CM have higher frequency than those with EM 
and because frequency was significantly correlated with self-efficacy (r = -.25, p < .001). Finally, 
disability was used as a covariate because of previously established relationships between 
disability and self-efficacy (Peck, 2013).  
 
Headache Variables  
Headache Disability.  As expected, a significant relationship existed between self-efficacy and 
disability (R2 = .061, p < .001). Table 2 presents the group differences on the main variables of 
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interest. Headache-related disability (HIT-6) scores differed significantly as a function of 
migraine diagnosis (p < .001). Episodic migraineurs without aura reported less disability 
compared to those with episodic migraine with aura (p < .001) as well as those with chronic 
migraine (p < .001). Additionally, chronic migraineurs had higher scores than those with 
episodic migraine with aura (p = .022).  
 
Headache-Related Self-Efficacy. Headache-related self-efficacy also differed significantly by 
migraine diagnosis (p < .001). Fisher’s least significant difference (LSD) post-hoc test illustrated 
that individuals with chronic migraine reported significantly lower self-efficacy than those with 
episodic migraine without aura (p < .001) and with aura (p < .001).   
 
Psychiatric Symptomatology Across Headache Groups.  Anxiety (DASS anxiety subscale) 
scores differed significantly by migraine diagnosis (p < .001). Fisher's LSD post-hoc test showed 
that this difference was due to the fact that individuals with episodic migraine without aura had 
significantly lower scores than those with episodic migraine with aura (p < .001) as well as those 
with chronic migraine (p < .001). Table 1 provides the mean scores on the DASS-A and other 
psychological measures as a function of migraine group.  
 As with the anxiety scale, depression (DASS depression subscale) scores also differed 
significantly by migraine diagnosis (p < .001). Post-hoc tests indicated that this difference was 
due to episodic migraineurs without aura scoring reporting significantly fewer symptoms of 
depression than those with episodic migraine with aura (F(2,828) = 2.133, p = .002), as well as 
those with chronic migraine (F(2,828) = 3.079, p < .001).  
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 Post-traumatic stress symptoms (PCL scores) also differed significantly between the 
migraine subtypes (p = .001). Post-hoc tests confirmed that individuals with episodic migraine 
without aura reported fewer symptoms of PTSD than those with episodic migraine with aura 
(F(2,793) = 4.138, p = .001) and those with chronic migraine (F(2,793) = 3.482, p = .012).   
 
Psychiatric symptoms and Self-efficacy 
 When examining the relationship between psychiatric comorbidities and headache-related 
self-efficacy, linear regression analysis revealed a modest but significant relationship (see Table 
3). Comorbid psychiatric symptoms of anxiety, depression, and PTSD explained a significant 
proportion of variance in self-efficacy scores, R2 = .047, F(3, 763) = 12.412, p < .001. To 
determine whether psychiatric symptoms remained associated with self-efficacy after controlling 
for the aforementioned covariates (i.e., gender, headache frequency, and disability), a 
hierarchical linear regression was conducted. Covariates were entered in block 1, and the 
psychiatric symptomatology scores were entered in step 2. Even after controlling for covariates, 
psychiatric comorbidities remained significantly associated with headache self-efficacy, though 
the percentage of unique variance accounted for was small (1.5%; p = .005).  
 
Discussion 
 Both psychological comorbidities and headache-related self-efficacy have been shown to 
affect disability, chronification, and treatment outcomes in migraine patients, but rarely has the 
interaction between these two domains been explored. The present study explored the 
relationship between psychological comorbidities and headache self-efficacy among individuals 
with migraine.   
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Headache Variables and Classification 
Analysis of various headache variables found significant differences within migraine 
subtypes in all variables studied. Specifically, people with chronic migraine experienced 
significantly increased headache-related disability, self-efficacy, and frequency in comparison 
with those diagnosed with episodic migraine with and without aura. The episodic migraine with 
aura group also showed significant increases in the areas of frequency, disability, PTSD, 
depression, and anxiety when compared those with migraine without aura. These results were 
comparable with previous studies of the same type (Bigal, Serrano, Reed, & Lipton, 2008; 
Lipton et al., 2007), and yet are novel in understanding symptomatology of migraine at different 
levels of frequency and as a function of aura.  
 
Psychiatric Comorbidities and Headache-Related Self-Efficacy 
 Consistent with our hypothesis, a significant inverse relationship was found between 
comorbid psychiatric symptoms and headache-related self-efficacy scores. This indicates that as 
psychiatric symptomatology increased, headache self-efficacy decreased proportionately. This 
relationship, though significant, was rather modest, with psychiatric symptoms only accounting 
for a small amount of variance in self-efficacy scores.   
Most past studies of self-efficacy have exclusively looked at its relationship with 
treatment outcomes (Sorbi et al., 2014; Thorne et al., 2007; Voerman et al., 2014), but our results 
contributes a non-clinical perspective.  A better understanding of headache self-efficacy outside 
of behavioral treatment is necessary for discerning on which headache variables self-efficacy has 
the greatest influence. By examining how headache-related self-efficacy relates to not only 
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migraine, but also comorbid disorders, we have gained a better understanding of both conditions. 
According to a review article by Wang, Chen, & Fuh (2010), there are 11 additional well-
established comorbid conditions with migraine. By examining the influence of headache 
variables on multiple comorbid conditions, the understanding of their relationship with self-
efficacy and headache impact can be improved. 
Finding only a modest association led us to question what other factors act as contributors 
of variance in headache-related self-efficacy. Headache frequency would be expected to have a 
large influence on self-efficacy because of its association with negative outcomes, and indeed its 
influence was reflected in the modest differential self-efficacy scores as a function of episodic 
versus chronic migraine frequency. 
The finding that two factors, psychiatric symptoms and frequency of headache attacks, 
previously considered to be major contributors to headache-related self-efficacy had only a 
modest association with self-efficacy was an unexpected finding. This finding suggests that 
headache-related self-efficacy is likely influenced by multiple variables, each accounting for 
small yet significant proportions of variance. In this notion, frequency of attacks and psychiatric 
comorbidities represent only two factors out of many others that collectively influence a 
migraineur’s headache self-efficacy. Previous studies reinforce this notion. For instance, both 
fear of pain and acceptance show modestly significant relationships with headache self-efficacy 
(Carpino, Segal, Logan, Lebel, & Simons, 2014; Kalapurakkel, S., Carpino, E.A., Lebel, A. & 
Simons, L.E., 2014) but were not assessed in the present study. Other variables, such as anxiety 
sensitivity, severity of headache pain, and average duration of headache attack, may also be 
valuable in predicting self-efficacy in migraine.  
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Strengths and Limitations  
This study had the benefit of a large and relatively diverse sample. Unlike past studies of 
the same type, this study utilized the full diagnostic interview for headache to determine 
migraine diagnosis, which lends increased validity to the results. Additionally, this study 
assessed the impact of several psychiatric symptoms at the same time. These variables are rarely 
examined concurrently and by doing so, we were able to gain a greater understanding of how 
they impact each other as well as self-efficacy. 
Despite these strengths, the present study has limitations. Because our data were collected 
from a college population of young adults, external validity as applied to older adults and 
treatment-seeking migraineurs is unclear. Possibly a larger effect of these psychiatric symptoms 
would be obtained among individuals seeking treatment. Additionally, since this is a cross-
sectional study, causality cannot be determined in the relationship between headache self-
efficacy and the psychiatric symptoms.  
  
Future Directions 
Future research into variables that affect headache-related self-efficacy would be valuable 
for piecing together a better understanding of its role in headache prognosis. Specifically, 
examining other headache variables such as fear of pain, headache severity, and attack duration 
could provide additional insight into influences on self-efficacy that were not assessed in this 
study. Another area of study to consider would be the relationship between self-efficacy and 
medication adherence.  Improved self-efficacy has been tied to better treatment adherence in 
other headache conditions, specifically chronic tension-type headache, and similar ameliorations 
may be found in migraine (Holroyd, Labus, & Carlson, 2009). These improved outcomes may 
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occur because if patients are confident in their ability to actually control their headache 
pharmacologically they may have greater adherence to their treatment regimen. Additionally, 
examining the relationship between headache self-efficacy and locus of control could prove 
valuable in furthering out understanding migraine. As locus of control is a similar construct to 
self-efficacy, investigating which of these variables has higher predictive utility in headache 
variables and outcomes could prove useful. 
With a better understanding of self-efficacy, non-pharmacological treatments could be 
improved to enhance migraine outcomes by specifically targeting self-efficacy. Increasing self-
efficacy as part of a non-pharmacological treatment could provide additional headache 
improvements insofar as it would facilitate adherence to treatment and utilization of skills during 
attacks.  
In conclusion and consistent with our hypothesis, a significant relationship exists between 
comorbid psychiatric symptoms and headache self-efficacy. This relationship, though significant, 
was not as strong as expected, with psychiatric symptoms only accounting for a small amount of 
variance in HSE scores. This small effect size likely indicates that numerous variables influence 
self-efficacy, and that psychiatric symptoms represent only one influential factor of many. 
Further study of other headache and psychological variables and self-efficacy, as well as the 
benefits of targeting self-efficacy in treatment, would be beneficial for further understanding 
self-efficacy and its role in headache.  
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Tables 
Table 1: Independent T-Tests 
 
Gender Differences in Pertinent Variables  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMSE - Management Self-Efficacy scale, HIT6 – Headache Impact Test, PCL – Post Traumatic Stress Check List, DASS-ANX 
– Depression Anxiety Stress Anxiety Subscale, DASS-DEP – Depression Anxiety Stress Depression Subscale 
* p < .05 vs females 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Differences Among Gender 
Mean Standard Deviation 
DASS-ANX 
     Male 
     Female 
 
7.53 
7.45 
 
7.72 
7.36 
DASS-DEP 
     Male 
     Female 
 
8.12 
7.44 
 
8.77 
8.37 
PCL 
     Male 
     Female 
 
33.58 
35.65 
 
13.59 
14.65 
HMSE 
     Male 
     Female 
 
108.67* 
104.66 
 
18.91 
21.28 
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Table 2: ANOVA results: Mean differences on variables of interest  
 
 Migraine  Omnibus p 
 
Chronic 
migraine 
n = 155 
Episodic 
migraine 
n = 484 
Episodic 
Migraine w/ 
aura 
n = 213 
 
HMSE 
97.14 
(21.4) 
108.05 
(19.8) 
105.66 
(21.9) 
< 0.001 
HIT6 
61.49 
(6.6) 
55.84 
(7.8) 
59.68 
(7.5) 
< 0.001 
PCL 
37.05 
(15.5) 
33.57 
(13.9) 
37.71 
(14.6) 
< 0.001 
DASS-ANX 
9.07 
(8.7) 
6.40 
(6.4) 
8.69 
(8.2) 
< 0.001 
DASS-DEP 
9.55 
(9.8) 
6.47 
(7.6) 
8.60 
(8.9) 
< 0.001 
DASS-STR 
14.39 
(9.0) 
10.56 
(7.7) 
13.87 
(9.1) 
< 0.001 
HA-Days Per Month 18.29 
(4.1) 
5.87 
(3.8) 
6.43 
(4.0) 
< 0.001 
 
HMSE - Management Self-Efficacy scale, HIT6 – Headache Impact Test, PCL – Post Traumatic Stress Check List, DASS-ANX 
– Depression Anxiety Stress Anxiety Subscale, DASS-DEP – Depression Anxiety Stress Depression Subscale, DASS-STR – 
Depression Anxiety Stress Subscale, HA-Days Per month – Headache days per month (frequency)  
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Table 3: Regression Analyses 
 
Block (Step) 
Predictor B 
95% CI for 
B 
P-
Value 
ΔR2 of 
Block Total R
2 
Headache Self-Efficacy (without covariates) 
1. Anxiety 
Depression 
PTSD 
-.30 
-.03 
-.20 
-.55, -.04 
-.26, -.04 
-.32, -.08 
.02 
.78 
.001 
0.05 
 
-- 
 
Headache Self-Efficacy (with covariates) 
1. Sex 
Frequency 
Disability 
.12 
-.60 
-.74 
-3.44, 3.67 
-.84, -.35 
-.93, -.55 
.95 
<. 001 
<. 001 
0.14 
 
2. Anxiety 
Depression 
PTSD 
-.19 
.07 
-.14 
-.43, .05 
-.15, .29 
-.25, -.03 
.12 
.55 
.01 
.015 .15 
Bolded ΔR2 values indicate statistically significant proportion of unique variance accounted for by Block  
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Appendix A 
Structured Diagnostic Interview for Headache-Revised 
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Appendix B 
Depression Anxiety Stress Scale-21 
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Appendix C 
Headache Impact Test 
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Appendix D 
Headache Management Self-Efficacy Scale 
 
HMSE-25 
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Appendix E 
Post Traumatic Tests Disorder Checklist 
 
 
